Surgical management of Chiari 1 Malformation in the paediatric population: A systematic review and meta-analyses of observational studies .

#### **Abstract**

## Background

Chiari 1 malformation(C1M) is a congenital malformation in the paediatric population is commonly encountered and often requires surgical management. Currently there is no agreed consensus on the appropriate and specific surgical technique for management of paediatric cases ofC1M. The aim of this systematic review and meta-analysis is to evaluate the clinical outcomes after posterior fossa decompression with duraplasty(PFDD) compared to posterior fossa decompression(PFD) alone in paediatric patients.

# Methodology

Systematic review of electronic literature databases searched from January 1997 to March 2017 of paediatric patients that had posterior fossa decompression with comparative analysis of PFD and PFDD were considered for inclusion. A Meta-analyses on the retrieved data was performed.

#### Results

Nine reports of eligible studies involving 3404 patients met the inclusion criteria. Of the 3404 patients, 1965 were treated with PFD alone while 1439 were treated with PFDD. Mean age range of 9.6 year to 11.1 years. Patients undergoing PFDD has significantly higher rates of pseudomeningocele formation OR 1.91, 95% C1 (1.30, 2.82) and lower complication rates OR 1.30, 95% CI (1.06, 1.61) than PFD. No significant difference in clinical improvement, reoperation rates, CSF leaks, wound infection and incidence of aseptic meningitis were observed

## **Conclusion**

PFDD is associated with fewer complications when compared to PFD alone. However the incidence of pseudomeningocoele formation is more commonly encountered following PFDD compared to PFD. PFDD is also more commonly performed following a failed improvement in symptomatology following PFD. Multicentre randomised controlled studies are needed to definitively identify the gold-standard technique for the management of answer to best surgical technique.

#### Introduction

Chiari malformation is a congenital malformation characterised by downward displacement of the cerebellar tonsils into the spinal canal [1]. There are four types of Chiari Malformation of which type 1 is the most common. The exact mechanism of Chiari malformation remain unclear and a matter of debate but majority of scholars speculate that it may be due to a small posterior fossa. This has been observed in several morphological studies of the posterior fossa [2]. One study reported a mean decrease in the volume of the posterior fossa vault and cerebrospinal fluid of 10% and 40% respectively [3]. According to the cranial-spinal dissociation theory proposed by Williams [4], the pressure gradient between two compartments exacerbates the tonsillar herniation and obstruction of CSF flow and displacement into the central canal resulting in syrinx formation.

Surgical treatment is the only widely accepted treatment for symptomatic C1M with or without a spinal cord syrinx [5]. There exists considerable debate regarding the extent of decompression and whether a durotomy or duraplasty should performed. There is consensus however that posterior fossa decompression heralds Rclinical and concurrent radiological improvement [6,7,8]. To achieve some authors adovocate removal of bone only, whilst others claim that opening the dura [ with or without duraplasty] is necessary for a favourable outcome [9, 10,]. Some authors stipulate that arachnoid should be opened and herniated cerebellar tonsils reduced by coagulation or partial tonsillectomy [5, 11]. However, there is no agreed consensus on the appropriate and specific surgical technique for management of C1M. The aim of this systematic review and meta-analysis is to evaluate the clinical outcomes after posterior fossa decompression with duraplasty compared to posterior fossa decompression alone in paediatric patients with C1M.

#### Material and methods

This review was conducted according to the Preferred Reporting Items for Systematic Reviews and meta-Analysis (PRISMA) guidelines for systematic review reporting and quality assessment of each trial using Cochrane collaboration tool for assessing risk bias [22]. This study is a systematic review with meta-analysis of non-RCTs with no restriction on the year of publication or language. This review included all full text non-RCTs comparing the clinical outcomes of posterior fossa decompression with or without duraplasty in paediatric patients with C1M.

Inclusion criteria were, paediatric patients with Chiari 1 malformation for surgical intervention of posterior fossa decompression with or without duraplasty. Non-RCTs, observational studies including cohort studies, case control studies or case series of more than ten patients were evaluated.

Exclusion criteria were case-series less than ten subjects, conference articles, abstracts, protocol, guidelines and animal studies.

The primary outcome measures were clinical improvement.

Secondary outcomes measures were re-operation rate, complication including CSF leak, pseudomeningocele, wound infection and aseptic meningitis

#### **Search methods**

Electronicliterature database search was performed from January 1997 to April 2017 in the following repositories; Cochrane Central Register of Controlled trials in the Cochrane library, Medline, Embase and Science Citation Index Expanded database. Key words were mapped to Medline medical subject heading (MESH) terms and searched for as text items. A filter was applied to filter out case reports and inappropriate studies from Medline and Embase. Hand searches of references of cited journals were conducted to further identify potential eligible articles for this review. Searches of reputable neurosurgical, neurology and neurosciences international conference journals were also conducted for eligible studies.

## **Data collection**

Required outcome data was collected by two reviewers who independently made the data extraction after reading the full text of all the included studies. Publication data, author, number of patients, interventions, study design, clinical improvement, recurrence rate, complication, CSF leak, re-operation rate and operation were documented. The data were further synthesised into a comprehensive summary of randomised trials table comparing both treatment outcomes.

#### Assessment of risk of bias in includes studies

The assessment of risk of bias was done on trials using the six main components of the Cochrane collaboration format [12] tool. Sequence generation, allocation concealment of participants, personnel and outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias were included.

# **Statistical Analysis**

The software package Review Manager 5.1 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, (Denmark) was used for data analysis. For dichotomous outcomes, the odds ratio (OR) or relative risk with 95% confidence interval (CI) was calculated using the Mantel-Hensel statistical method for the meta-analysis. For data with zero events, risk difference was calculated and used for the mortality results. For continuous outcomes, the mean difference with 95% CI was used, and the estimated result was used for the meta-analysis.

For OR (Odd Ratio) and mean differences outcomes, we used the random-effects and fixed-effects models. If there were no differences between the results of the 2 models, the fixed-effects model was reported. If differences existed in the intervention effects, the random-effects and fixed-effects models were reported. If statistical heterogeneity existed, the random-effects model was reported. Heterogeneity was explored using  $\chi^2$  test to provide an indication for between-study, heterogeneity was considered significant when  $I^2 \geq 50\%$  or when X- square test resulted in P < 0.05. Statistical heterogeneity for each pooled summary was estimated using  $I^2$ statistics presented as a percentage. A careful review of studies was

conducted to identify any findings of significant heterogeneity. A funnel plot of trials undergoing meta-analysis was used to determine if any publication bias existed in outcomes involving data from the trials.

# Validity Assessment

Validity assessment was carried out according to risk of bias guidelines specified in the *Cochrane Handbook for Systematic Reviews of Interventions* by Akhigbe T, Zolnourian A and Sadek AR with differences resolved through discussion. The risks of bias including six criteria were analysed: random sequence generation, allocation concealment, incomplete outcome data, selective reporting, and other biases. Validity assessment scoring and weighting tools were not used as per Cochrane recommendations. In surgical trials, blinding of participants and personnel is difficult and unfeasible and was not considered for this review.

#### **Results**

The literature search identified 901 studies, including 524 in Medline, 351 in Embase and 11 in the Cochrane Central Register of Controlled Trial. Internet-based registry search yielded seven; journal search yielded four studies conference proceedings one and references two. After further screening by the investigative team, 38 out of 901 studies were extracted for full text review, and 29 out of these studies were excluded because they were narrative literature reviews of inappropriate intervention and studies involving adult patients. Eighteen studies were finally included for systematic review and meta-analyses. There were total 3404 patients who underwent posterior fossa decompression with or without duraplasty.

## **Study Characteristics**

Extensive database search identified nine non-RCTs [13-21] with 3404 patients [Table 1]. A total of 3404 paediatric patients who underwent surgical treatment for Chiari 1malformation were described in nine included studies. Of these 1439 had PFDD compared to 1965 that had PFD alone. Patient age ranged 9.6 to 11.1 years. Presence of synrigomyelia was mentioned in some of the studies. Follow-up ranged from 5 months to 2 years but was largely unaddressed by majority of the studies. No blinded outcome assessment was specified in any of the studies.

## **Critical Appraisal**

Methodological quality was assessed by Newcastle-Ottawa scale (NOS) [22] scoring of included studies (Table 2). NOS is a tool for assessing the quality of nonrandomised studies in meta-analyses. Study quality scores ranged from 4 to 8 out of possible 9 points. Scoring for comparability was poor because insufficient details about patients selection of varied surgical techniques. Potential confounding variables were addressed by three studies [18, 19, 21]. Varied outcome due to report inconsistencies across studies

## Assessment of risks of bias of RCTs

The assessment of risk of bias was done on the RCTs using the six main components of the Cochrane tool. Sequence generation, allocation concealment, blinding of participants, personnel and outcome assessor, incomplete outcome data, selective outcome reporting and other sources of bias were included.

### **Outcome measure**

## **Clinical Improvement**

Four studies [13, 16, 18, 20] recorded the clinical improvement rate between the two groups with total of 148 patients, 26 out 68 for PFD and 50 out of 86 for PFDD, there was no difference between the two group, [1.84, 95% CI (0.89, 3.82), P <0.05]. Study by Lamondi et al [21] used a novel outcome scale with scores ranging from 1 to 2 points and demonstrated greater clinical improvement in patients who had PFD as compared to PFDD although this did not reach statistical significance.

# Reoperation

Four studies [14, 18, 19, and 20] recorded the incidence of re-operation. Of the 1178 patients who underwent a PFD 25 underwent a second procedure to manage there ongoing symptoms. Of the 1697 cases undergoing a PFDD 26 underwent a further procedure.. No statistical difference in the incidence of either procedure resulting in a second procedure to manage ongoing symptoms was observed 1.33, 95% CI (0.77, 2.31).

#### **CSF Leak**

Two studies [13, 14] reported CSF leak. Patients that had PFD were more like to have CSF leak in comparison to PFDD patients this however was not observed to be statistically significant 0.90, 95% CI (0.65, 1.26).

# Pseudomeningocele

Three studies [14, 15, 17] reported pseudomeningocele as complication, PFDD patients are significantly more likely to develop pseudomeningocele in comparison to PFD OR 1.91 95% CI (1.30, 2.82), P=0.001

# **Wound Infection**

One study [13] reported wound infection. There was no predilection for wound infection in either of the surgical techniques.

# **Aseptic Meningitis**

Four studies [14, 18, 19, and 21] reported aseptic meningitis with PFD less likely to develop aseptic meningitis in comparison to PFDD ?stats?.

# Overall complication {whats the definition of overall complications?- needs to be defined in the text}

Four studies [14, 18, 19, 21) reported overall complication. PFD patients are significantly more likely to have more complications than PFDD. OR 1.30 95% CI(1.06, 1.62), P=0.01

#### **Discussion**

C1M is herniation of cerebellar tonsil below the level of foramen magnum into the upper cervical spine and is commonly associated with syringomyelia as a result of deranged CSF dynamics [23]. There is a consensus that asymptomatic patients with C1M do not require surgical intervention[24]. However, symptomatology is an indication for surgery, with tussive headaches, neck, arm or back pain, swallowing difficulties, drop attacks, upper extremity sensory disturbance and presence of syrinx being critical cues for surgical intervention[25]. The results of our meta-analysis of studies comparing PFD with PFDD suggest that patients who had PFDD encounter fewer post-operative complications but are move likely to develop a pseudomeningocoele.

Post-operative symptomatic clinical improvement

Reoperation rate was reported by various authors[13,16] to evaluate the effectiveness of PFD and PFDD in the management of CM-1 which may be as a result of persistent symptoms or possibly due to complication, but reasons as to why patients underwent a second procedure were not clearly stated in these studies. Our study has shown there to be no difference between the two groups with respect to the rate of re-operation for the management of ongoing or worsening symptoms.

Follow-up data is sparse and was absent from five studies of the studies included in the metaanalysis [ 14, 17, 18, 19, 20] Data from the remaining studies heralded an mean follow-up time of 1.4 years.

# Conclusion

PFDD can be considered as a preferable technique for CM-1 and also tend to be considered in case of failed PFD however PFDD is associated with higher rate of pseudomenigocele.




Fig 1: Flow diagram of study search

Table 1 Study Characteristics

| Study/ year        | Operation<br>PFD/PFDD | Total | Mean Age YRS | Study Design         | Follow up<br>(years) |  |
|--------------------|-----------------------|-------|--------------|----------------------|----------------------|--|
| Les 2014           | 29/36                 | 65    | 9.6          | Retrospective cohort | 2                    |  |
| Shweikeh<br>2014   | 1593/1056             | 2649  | 10.3         | Retrospective cohort | NA                   |  |
| MutchnInk<br>2010  | 56/64                 | 120   | 11.1         | Retrospective cohort | 0.5                  |  |
| Galarza 2007       | 20/21                 | 41    | 10.4         | Retrospective cohort | 1.8                  |  |
| McGirt 2007        | 151/128               | 256   | 10           | Retrospective cohort | NA                   |  |
| Yet 2006           | 40/90                 | 130   | 9.2          | Prospective cohort   |                      |  |
| Limonadi<br>2004   | 12/12                 | 24    | 9.6          | Prospective cohort   | 1.3                  |  |
| Navarro<br>2004    | 56/24                 | 80    | 9.5          | Retrospective cohort | NA                   |  |
| Ventureyra<br>2003 | 8/8                   | 16    | 10.5         | Retrospective cohort | NA                   |  |

NA: Not available

Table 2: Newcastle-Ottawa Scale Scoring of Included Studies

| Author & year   | Selection     | Comparability  | Outcome        | Total Score |
|-----------------|---------------|----------------|----------------|-------------|
|                 | (4 point max) | (2 points max) | (3 points max) |             |
| Lee 2014        | 3             | 1              | 2              | 6           |
| Shweikeh 2014   | 4             | 2              | 1              | 7           |
| Mutchnik 2010   | 3             | 1              | 1              | 5           |
| Galarza 2007    | 3             | 0              | 1              | 4           |
| McGirt 2007     | 3             | 1              | 1              | 5           |
| Yeh 2006        | 3             | 1              | 2              | 6           |
| Limonadi 2004   | 4             | 1              | 3              | 8           |
| Navarro 2004    | 3             | 1              | 2              | 6           |
| Ventureyra 2003 | 3             | 0              | 1              | 4           |

**Selection**- one point for each of the following: representativeness of exposed cohort, selection of non-exposed cohort, attainment of exposure and no outcome of interest at the start.

**Comparability**- One point awarded if study controls for 1 important factor and 1 additional point if study controls >1 important factor

**Outcome**- One point awarded for each of the following: assessment of outcome, adequate length of follow up and adequacy of follow up

| Outcomes                 | Numbe<br>r of<br>studies | Number<br>of<br>patients | PFD          | PFDD         | Model | OR (95%<br>CI)        | <i>I</i> <sup>2</sup> (%) | Ph    |
|--------------------------|--------------------------|--------------------------|--------------|--------------|-------|-----------------------|---------------------------|-------|
| Reoperation              | 4                        | 2875                     | 25/1178      | 26/1697      | FE    | 1.33[0.77,<br>2.31]   | 76                        | 0.31  |
| Clinical<br>Improvement  | 4                        | 148                      | 26/62        | 50/86        | FE    | 1.84 [0.89,<br>3.82]  | 0                         | 0.10  |
| CSF Related complication | 2                        | 2694                     | 98/1602      | 62/1092      | FE    | 0.90 [0.65,<br>1.26]  | 0                         | 0.54  |
| Pseudomeni<br>ngocoele   | 3                        | 3025                     | 47/1765      | 60/1260      | FE    | 1.91 [1.30,<br>2.82]  | 0                         | 0.001 |
| Wound infection          | 1                        | 65                       | 1/29         | 0/36         | FE    | 0.26 [0.01,<br>6.63]  | 0                         | 0.42  |
| Aseptic<br>Meningitis    | 2                        | 89                       | 0/41         | 4/48         | FE    | 4.80 [0.53,<br>43.50] | 0                         | 0.16  |
| Overall complication     | 4                        | 2883                     | 221/170<br>1 | 188/118<br>2 | FE    | 1.30[1.06,<br>1.62]   | 0                         | 0.01  |

Table 3: Outcome of meta-analysis




Figure 2: Clinical Improvement




Figure 3: Reoperation




Figure 4: CSF leak




Figure 5: Pseudomeningocele




Figure 6: Wound Infection




Figure 7: Aseptic Meningitis

|   | PFD    | D     | PFE    | )     |        | Odds Ratio          |  | Odds Ratio         |
|---|--------|-------|--------|-------|--------|---------------------|--|--------------------|
| Study or Subgroup                                     | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI  |  | M-H, Fixed, 95% CI |
| Limonadi 2004   | 1      | 12    | 0      | 12    | 0.3%   | 3.26 [0.12, 88.35]  |  | -                  |
| Navarro 2004  | 9      | 24    | 2      | 56    | 0.5%   | 16.20 [3.16, 83.14] |  |                    |
| Shweikeh 2014   | 169    | 1056  | 217    | 1593  | 97.5%  | 1.21 [0.97, 1.50]   |  |                    |
| Yeh 2006  | 9      | 90    | 2      | 40    | 1.7%   | 2.11 [0.43, 10.25]  |  |                    |
| Total (95% CI)  |        | 1182  |        | 1701  | 100.0% | 1.30 [1.06, 1.61]   |  | <b>•</b>           |
| Total events  | 188    |       | 221    |       |        |                     |  |                    |
| Heterogeneity: Chi²= 10.24, df= 3 (P = 0.02); l²= 71% |        |       |        |       |        | 0.04                | 04 40 400                                |                    |
| Test for overall effect: Z = 2.47 (P = 0.01)          |        |       |        |       |        | 0.01                | 0.1 1 10 100<br>Favours PFDD Favours PFD |                    |

Figure 8: Overall complication




Figure 9: Risk of bias graph




Figure 10: Risk of bias

# Reference

 DA. Dagtekin, E. Avci, E. Kara, D. Uzmansel, O. Dagtekin, A. Koseoglu, D. Talas, C. Bagdatoglu Posterior cranial fossa morphometry in symptomatic adult Chiari I malformation patients: comparative clinical and anatomical study. Clin Neurol Neurosurg, 113 (2011), pp. 399–403

- 2. S. Aydin, H. Hanimoglu, T. Tanriverdi, E. Yentur, M.Y. Kaynar. Chiari type I malformations in adults: a morphometric analysis of the posterior cranial fossa Surg Neurol, 64 (2005), pp. 237–241 discussion 241.
- 3. T.H. Milhorat, M.W. Chou, E.M. Trinidad, R.W. Kula, M. Mandell, C. Wolpert, et al. Chiari I malformation redefined: clinical and radiographic findings for 364 symptomatic patients. Neurosurgery, 44 (1999), pp. 1005–1017.
- 4. B. Williams. The distending force in the production of communicating syringomyelia Lancet, 2 (1970), pp. 41–42.
- 5. Hankinson T, Tubbs RS, Wellons JC. Duraplasty or not? An evidence based review of the pediatric Chiari 1 malformation. Childs Nerv, Syst 2011; 27:35-40
- 6. N.M. El-Ghandour.Long-term outcome of surgical management of adult Chiari I malformation.Neurosurg Rev, 35 (2012), pp. 537–546
- 7. Imprerato A, Seneca V, Cioffi V, Colella G Gangemi M. Treatment of Chiari 1malformation: who, when and how. Neuroll Sci 2011; 32(Suppl 3) S335-339.
- 8. Tisell M. Wallskog J, Linde M: Long-term outcome after surgery after surgery for Chiari 1 malformation. Acta Neurol Scand 2006; 120: 295-299
- 9. U. Batzdorf, D.L. McArthur, J.R. Bentson. Surgical treatment of Chiari malformation with and without syringomyelia: experience with 177 adult patients. J Neurosurg, 118 (2013), pp. 232–242
- 10. Alfieri A, Pinna G. Long-term results after posterior fossa decompression in synringomyelia with adult Chiari 1 malformation. J Neurosurg Spine 2012; 17: 381-7
- 11. Klekamp J. Surgical treatment of Chiari 1 malformation analysis of intraoperative findings, complications, and outcome for 371 foramen magnum decompressions. Neurosurgery 2012; 71: 365-80
- 12. reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg, 8 (2010), pp. 336–341.
- 13. Lee A, Yarbrough CK et al. Comparison of posterior fossa decompression with or without duraplasty in children with type 1 Chiari malformation. Childs Nerv Syst 2015;30: 419-424.
- 14. Shweikeh F, Sunjaya D. National treand, complications and hospital charges in patients with Chiari malformation type 1 treated with posterior fossa decompression with or without duraplasty. Pediatr Neurosurg 2014-15;50:31-37.
- 15. Mutchnick IS, Janjua RM et al. Decompression of Chiari 1 malformation with or without duraplast: morbidity versus recurrence. J Neurosurg Pediatr 2010;5: 474-478
- 16. Galarza M, Sood S, Ham S. Relevance of surgical strategies for the management of pediatric chiari type 1 malformation. Childs nerv Syst 2007; 23:691-696
- 17. McGirt MJ, Attenello FJ et al. Intraoperative ultrasonograpy as a guide to patient selection of duraplasty after suboccipital decompression in children with chiari malformation type 1. J Neurosurg 2008;2: 52-57
- 18. Yeh DD, Koch B et al. Intraoperative sonography to determine the extent of surgery necessary during posterior fossa decompression in children with Chiari malformation type 1. J Neurosurg 2006; 105:36-32
- 19. Novarro R, Olavarria G et al. Surgical results of posterior fossa decompression for patients with Chiari 1 malformation. Childs Nerv Syst 2004;20:349-356
- 20. Ventureyra ECG, Aziz HA et al. The role of cine flow MRI in children with Chiari 1 malformation. Childs Nerv Syst 2003;19: 109-113

- 21. Limonadi FM, Selden NR. Dura-splitting decompression of craniocervical junction: reduced operative time, hospital stay and cost with equivalent early outcome. J Neurosurg 2004;101: 184-188
- 22. Wells GA, Shea B, O'Connell D, Peterson J, Welch V Losos M et al: The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa: Department of Epidemiology and Community Medicine, University of Ottawa.
  <a href="mailto:(http://www.ohri.ca/programs/clinical\_epidemiology/oxford.htm">http://www.ohri.ca/programs/clinical\_epidemiology/oxford.htm</a>) [Accessed 25 April 2017]
- 23. Tubbs RS, McGirt MJ et al. Surgical experience in 130 pediatric patients with Chiari 1 malformation. J NEUROSURG 2003; 99: 291-296
- 24. Haines SJ, Berger M. Current treatment of Chiari malformations type 1 and II. A survey of pediatric section of American Association of Neurological Surgeons. Neurosurgery 1991; 28(3): 353-357
- 25. Cahan LD, Bentson JR. Consideration in the diagnosisi and treatment of syringomyelia and the Chiari malformation. J Neurosurg 1982;57: 24-31
- 26. Chotai S, Medhkour A. Surgical outcomes after posterior fossa decompression with or without duraplasty in Chiari malformation-1. Clin neuro Neurosurg 2014; 125: 182-188